P3‐374: Treatment by addition in Alzheimer's disease: Rationale for combination therapy with galantamine and memantine—Efficacy and safety

Abstract

Alzheimer's has no current cure, but treatments for symptoms are available and research continues. Although current Alzheimer's treatments cannot stop Alzheimer's from progressing, they can temporarily slow the worsening of symptoms and improve quality of life for those with Alzheimer's and their caregivers. Today, there is a worldwide effort under way to find better ways to treat the disease, delay its onset, and prevent it from developing.Considering the moderate clinical state the Alzheimer's disease, without therapeutic response or poor therapeutic response with an anti dementia agent, we try improvement the therapeutic response with 2 drugs association. The efficacy, safety, and tolerability of cholinergic agent: galantamine and moderate affinity NMDA-receptor antagonist: memantine, were assessed taking into account the profile of patients with neurocognitive disorder: Alzheimer's disease, from the clinical aspects and the different classifications. The experience included 428 patients who were enrolled in a prospective, observational, multicenter, and open-label study to receive 16 mg/day of galantamine and 30 mg/day of memantine for 12 months of treatment of addition. The therapeutic response was measured using the mini-mental state examination (MMSE), Clinical Dementia Rating (CDR), Alzheimer's Disease Assessment Scale (ADAS-GOG), Functional Activities Questionnaire (FAQ) the Clinical Global Impression Scale (CGI) and the UKU scale of adverse effects.Taking into account the efficacy, safety and adverse events of the treatment, the final results of the study showed that galantamine with addition memantine improve cognition, behavioural symptoms, and the general well-being of patients with cognitive impairment: Alzheimer's disease. The incidence of adverse events was not significant and a very good profile of tolerability and safety was observed. At the conclusion of this session, we should be able to demonstrate with use the association memantine - galatamine in neurocognitive disorder: Alzheimer's disease, improve cognition, behavioural symptoms, and the general state recognized as neurocognitive disorder. Discussion: Suggest that before Alzheimer's disease continues evolution to a severe state, the pharmacological use this association to slowing or stopping the dementia process.